Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data
BackgroundZolbetuximab is a novel monoclonal antibody targeting CLDN18.2 for advanced gastric or gastroesophageal junction adenocarcinoma. However, its large-scale, real-world safety profile remains incompletely characterized. This study aimed to analyze its post-marketing adverse events using the F...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2026-07-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1787423/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|